<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Sulfamethoxazole-Trimethoprim - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Sulfamethoxazole-Trimethoprim</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Sulfamethoxazole-Trimethoprim</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Sulfamethoxazole-Trimethoprim 800/160mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Urinary tract infection (uncomplicated cystitis)</strong>
            <ul>
              <li>1 double-strength (DS) tablet (800/160 mg) PO twice daily for 3 days</li>
              <li>Alternative regimen: 3–5 days if clinical response uncertain or complicated factors</li>
            </ul>
          </li>
          <li><strong>Urinary tract infection (complicated / pyelonephritis)</strong>
            <ul>
              <li>1 DS tablet PO twice daily for 7–14 days (duration depends on severity and response)</li>
              <li>Consider alternate agents if severely ill or local resistance high</li>
            </ul>
          </li>
          <li><strong>Skin and soft tissue infection (MRSA-suspected)</strong>
            <ul>
              <li>1–2 DS tablets PO twice daily for 5–10 days depending on severity and response</li>
              <li>Typical outpatient dose: 1 DS tablet twice daily</li>
            </ul>
          </li>
          <li><strong>Pneumocystis jirovecii pneumonia (PCP) prophylaxis</strong>
            <ul>
              <li>1 DS tablet PO daily (or 1 single-strength tablet daily as alternative)</li>
              <li>Follow local immunocompromised patient protocols</li>
            </ul>
          </li>
          <li><strong>Pneumocystis jirovecii pneumonia (PCP) treatment</strong>
            <ul>
              <li>15–20 mg/kg/day (based on trimethoprim component) divided every 6–8 hours for 21 days</li>
              <li>Typical adult dose: 2 DS tablets PO three times daily (or 4 DS tablets twice daily)</li>
              <li>Requires close monitoring; often managed with medical direction/evacuation</li>
            </ul>
          </li>
          <li><strong>Traveler's diarrhea (treatment; if bacterial suspected and appropriate)</strong>
            <ul>
              <li>1 DS tablet PO twice daily for 3–5 days</li>
              <li>Not first-line in many regions due to resistance; consider fluoroquinolone or azithromycin per local guidelines</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Urinary tract infections (uncomplicated and complicated; susceptible organisms)</li>
          <li>Skin and soft tissue infections (including MRSA coverage)</li>
          <li>Acute bacterial exacerbation of chronic bronchitis (selected cases)</li>
          <li>Pneumocystis jirovecii pneumonia prophylaxis and treatment (immunocompromised patients)</li>
          <li>Traveler's diarrhea (when susceptibility likely and other agents not preferred)</li>
          <li>Selected other infections per susceptibility and guidelines (e.g., toxoplasmosis, nocardiosis)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to sulfonamides or trimethoprim (including severe cutaneous reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis)</li>
          <li>Pregnancy: contraindicated in first trimester and at term (risk of kernicterus in neonate); use with caution in second trimester only if benefit outweighs risk</li>
          <li>Breastfeeding: avoid in infants &lt;2 months, G6PD deficiency, prematurity, or hyperbilirubinemia</li>
          <li>Severe renal impairment (CrCl &lt;15 mL/min): contraindicated; dose adjustment required for moderate impairment</li>
          <li>Severe hepatic impairment</li>
          <li>Megaloblastic anemia due to folate deficiency</li>
          <li>Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of hemolysis)</li>
          <li>Caution with concurrent medications: warfarin (INR monitoring), methotrexate, phenytoin, sulfonylureas</li>
          <li>Hyperkalemia risk: caution with renal impairment, high-dose therapy, ACE inhibitors, ARBs, potassium-sparing diuretics</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset (nausea, vomiting, diarrhea, anorexia)</li>
          <li>Rash (common; ranges from mild to severe/life-threatening)</li>
          <li>Hypersensitivity reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)</li>
          <li>Hematologic: bone marrow suppression, thrombocytopenia, leukopenia, megaloblastic anemia</li>
          <li>Hyperkalemia (especially with high doses, renal impairment, or concurrent ACE inhibitors/ARBs)</li>
          <li>Renal: crystalluria, interstitial nephritis, acute kidney injury</li>
          <li>Hepatotoxicity (elevated liver enzymes, cholestatic jaundice)</li>
          <li>Photosensitivity</li>
          <li>C. difficile-associated diarrhea</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Take with full glass of water; maintain adequate hydration to reduce crystalluria risk</li>
          <li>May take with or without food (food may reduce GI upset)</li>
          <li>Space doses evenly (e.g., 12 hours apart for twice-daily dosing)</li>
          <li>Complete full course unless severe adverse reaction occurs</li>
          <li>Sun protection: advise use of sunscreen and protective clothing (photosensitivity risk)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (symptoms, fever)</li>
          <li>Rash: stop immediately if severe rash, mucosal involvement, or systemic symptoms (possible SJS/TEN)</li>
          <li>CBC if prolonged therapy or high-risk patient (monitor for cytopenias)</li>
          <li>Renal function and electrolytes (especially potassium) if available and patient at risk</li>
          <li>INR monitoring if on warfarin (increased bleeding risk)</li>
          <li>Adequate hydration (ensure good urine output)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Antibiotic stewardship: confirm indication and consider local resistance patterns (SMX-TMP resistance common in some regions for UTI and GI infections)</li>
          <li>Rash vigilance: educate patient to report rash immediately; stop drug and seek evaluation if severe or progressive</li>
          <li>Hydration critical: ensure adequate fluid intake, especially in hot environments, to prevent crystalluria and renal complications</li>
          <li>Drug interactions: review medication list carefully (warfarin, ACE inhibitors, ARBs, methotrexate, sulfonylureas)</li>
          <li>Limited labs: be conservative in older adults, renal impairment, or prolonged courses; consider alternative agents if monitoring not feasible</li>
          <li>Document allergy history: important to distinguish true allergy from intolerance for future prescribing</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (sulfamethoxazole-trimethoprim / Septra DS): <a href="https://pdf.hres.ca/dpd_pm/00042485.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00042485.PDF</a></li>
          <li>Health Canada product monograph (APO-sulfatrim DS): <a href="https://pdf.hres.ca/dpd_pm/00053085.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00053085.PDF</a></li>
          <li>RxFiles UTI Management: <a href="https://www.rxfiles.ca/rxfiles/uploads/documents/UTI-Cystitis.pdf" target="_blank" rel="noopener">https://www.rxfiles.ca/rxfiles/uploads/documents/UTI-Cystitis.pdf</a></li>
          <li>Choosing Wisely Canada – Antibiotics for UTI: <a href="https://choosingwiselycanada.org/recommendation/family-medicine/" target="_blank" rel="noopener">https://choosingwiselycanada.org/recommendation/family-medicine/</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
